Aceto (ACTE) is lower in pre-market trading after the company reported late Thursday that financial results for Q3, or the quarter ended March 31, 2014, declined from the prior year period, and fell short of Street estimates.
Shares are down 8.74% at $21.00 with a 52-week range of $10.01 – $25.25.
The company, which markets, sells and distributes products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, reported Q3 earnings of $0.19 per share, compared with the prior-year period’s $0.28 per share. Revenue was $124.8 million, down 17.3% from $150.9 million in the same quarter last year.
Two analysts on Capital IQ had an average estimate of $0.28 for EPS and $142.02 million for revenue.
Latest posts by Kevin Calderon (see all)
- Researchers Found Live Giant Shipworm That Feeds On Sulfur? - Apr 19, 2017
- Hawaiian Telescope Led To The Discovery Of A Primordial Galaxy - Apr 14, 2017
- Neuralink Is Elon Musk’s Way Of Developing New AI Systems - Apr 8, 2017